RxDoctor Payments Data

Justin Miles, MD

Psychiatry · Minneapolis, MNNPI 1881984441

Payments from drug & device makers

$342in general payments, 2019–2025

Across 19 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vanda Pharmaceuticals Inc.$92
  • Supernus Pharmaceuticals, Inc.$82
  • Neurocrine Biosciences, Inc.$49
  • Takeda Pharmaceuticals U.S.A., Inc.$27
  • Almatica Pharma LLC$24
  • Lundbeck LLC$20
  • plus $47 from 3 others

What the payments were for

  • Food & beverage$342100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$342 in reported general payments places this provider in the 85th percentile of 552 psychiatry providers in Minnesota.

See all psychiatry providers in Minnesota

Medicare billing

Part B allowed, 2024
$209,376
Medicare patients
570
Services billed
1,801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate87$728,549
Invega SustennaPaliperidone Palmitate131$363,771
Abilify MaintenaAripiprazole48$135,605
Austedo XrDeutetrabenazine17$117,698
VraylarCariprazine Hcl72$96,316
LybalviOlanzapine/Samidorphan Malate56$92,264
RexultiBrexpiprazole51$82,083
TrintellixVortioxetine Hydrobromide96$53,241
Olanzapine933$52,943
Risperidone ErRisperidone Microspheres41$47,047
Risperdal ConstaRisperidone Microspheres26$46,582
Aripiprazole407$46,455
Clozapine596$40,346
Quetiapine Fumarate850$33,741
BelsomraSuvorexant65$27,904

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$49$728,54987 claims
Johnson & JohnsonInvega Sustenna, Risperdal Consta$14$410,352157 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Adderall, Vyvanse$27$68,642128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 552 psychiatry providers in Minnesota.

Other psychiatry in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →